Oxford Biomedica, Smith & Nephew 'vulnerable' to takeover
RBC anticipates more takeovers in the healthcare space after a flurry of recent bids for mid-cap listed assets
Company
Oxford BioMedica PLC
LON:OXB
Oxford BioMedica is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how.
69 stories · page 2 of 4
Oxford Biomedica in deal with Homology to set up new AAV manufacturing and innovation business
The company also said it will raise £80mln in a placing
Oxford Biomedica inks licence and supply deal for LentiVector with Cabaletta Bio
US-based Cabaletta Bio develops engineered T cells designed to treat patients with autoimmune diseases
Oxford Biomedica doubles financial guidance after AstraZeneca increases COVID-19 vaccine production
The group is a key manufacturer of what is known as the Oxford/AstraZeneca jab
Oxford Biomedica 'buy' recommendation reiterated as COVID-19 vaccine manufacturer's revenues soar
With revenues rolling in from the COVID-19 vaccine the group is expecting another year of strong top-line growth.
Oxford Biomedica clinches CAR-T cell therapies collaboration with PhoreMost
The programme aims to develop next-generation cell therapies with improved efficacy and durability
Oxford Biomedica receives approval for COVID-19 vaccine candidate manufacturing site
The approval completes a phase of expansion that more than doubles the group's manufacturing capacity compared to 2019
Oxford Biomedica, AstraZeneca sign agreement to produce COVID-19 vaccine candidate
Oxford Biomedica will receive £15mln upfront as a capacity reservation fee, plus additional revenue in excess of £35mln
Oxford Biomedica secures third partnership in CAR-T field
NASDAQ-listed Beam Therapeutics signed up to use the firm's LentiVector platform in its projects
The four coronavirus vaccine candidates to watch
Oxford University, Moderna, Johnson & Johnson and a partnership between Pfizer and BioNTech are developing the lead candidates, according to experts
Archive
Oakley Capital Investments bounces as it nets £99mln from sale of Inspired stake
A look at some of the major risers and fallers in London on Wednesday
Oxford Biomedica shares jump as Novo Holdings pays £53.5mln for 10% stake in the firm
Oxford said the proceeds of the investment will be used to repay debt and develop its products
Investments and investor services
Tertiary Minerals higher after announcing a new project acquisition in Nevada
A look at the day's major movers, including Pressure Technologies. Clontarf Technologies, Oxford Biomedica, Trafalgar Property, Yü, Proton Power and Frontier IP
Archive
FTSE 100 closes higher as no deal Brexit fears ease
Footsie closed around 26 points higher at 7,185, while FTSE 250 added around 103 points at 19,283
Archive
Thursday's Brexit fallout likely to overshadow Capita and Savills results
Brexit and the latest vote will likely be the main talking point, but there will be financial results too!
Two huge licensing deals help Oxford BioMedica swing to a first-half profit
Oxford signed deals with Bioverativ and Axovant, which could be worth upwards of US$1bn over the next few years
FTSE 100 finishes lower as BoE keeps rates on hold; sterling gains
The UK benchmark index of leading shares finished down nearly 32 points at 7,281
Investments and investor services
Morrisons in the spotlight as discounters are seeing a slowdown
The supermarket is the likely standouts in Thursday's market diary.
Archive
Heatwave may help or hurt sales at Wetherspoons, JD Sports, Primark and Dunelm
The week ahead includes annual results from Wetherspoons, Galliford Try and Dunelm along with interims from Morrisons and trading updates from AB Foods and Ashtead
CAR-T therapies: All you wanted to know and were too afraid to ask
Immuno-oncology has become a popular field of research with UK companies at the forefront of the latest innovations